Enhancing Anticancer Effect of Gefitinib across the Blood–Brain Barrier Model Using Liposomes Modified with One α-Helical Cell-Penetrating Peptide or Glutathione and Tween 80

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI), such as gefitinib, have been demonstrated to effectively treat the patients of extracranial non-small cell lung cancer (NSCLC). However, these patients often develop brain metastasis (BM) during their disease course. The major...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Kuan-Hung, Hong, Shu-Ting, Wang, Hsiang-Tsui, Lo, Yu-Li, Lin, Anya Maan-Yuh, Yang, James Chih-Hsin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5187798/
https://www.ncbi.nlm.nih.gov/pubmed/27916828
http://dx.doi.org/10.3390/ijms17121998

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5187798/
https://www.ncbi.nlm.nih.gov/pubmed/27916828
http://dx.doi.org/10.3390/ijms17121998

Ejemplares similares